| Original language | English (US) |
|---|---|
| Pages (from-to) | 717-718 |
| Number of pages | 2 |
| Journal | Neurology |
| Volume | 79 |
| Issue number | 7 |
| DOIs |
|
| State | Published - Aug 14 2012 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. / Rutherford, Nicola J.; Carrasquillo, Minerva M.; Li, Ma; Bisceglio, Gina; Menke, Joshua; Josephs, Keith A.; Parisi, Joseph E.; Petersen, Ronald C.; Graff-Radford, Neill R.; Younkin, Steven G.; Dickson, Dennis W.; Rademakers, Rosa.
In: Neurology, Vol. 79, No. 7, 14.08.2012, p. 717-718.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease
AU - Rutherford, Nicola J.
AU - Carrasquillo, Minerva M.
AU - Li, Ma
AU - Bisceglio, Gina
AU - Menke, Joshua
AU - Josephs, Keith A.
AU - Parisi, Joseph E.
AU - Petersen, Ronald C.
AU - Graff-Radford, Neill R.
AU - Younkin, Steven G.
AU - Dickson, Dennis W.
AU - Rademakers, Rosa
N1 - Funding Information: Study funding: Supported by the National Institute of Health grant P50 AG16574 (to R.C.P., D.W.D., N.R.G.-R., and R.R.), R01 NS065782 (to R.R.), R01 AG26251 (to R.R.), R01 AG 037491 (to K.J.) , and the Consortium for frontotemporal dementia (to R.R.). Funding Information: Disclosure: N. Rutherford, M. Carrasquillo, M. Li, G. Bisceglio, and J. Menke report no disclosures. K. Josephs receives research support from the NIH and The Dana Foundation. J. Parisi serves as a Section Editor for Neurology® and receives research support from the NIH. R. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth, Pharmaceuticals, and GE Healthcare, and receives research support from the NIH. N. Graff-Radford serves on a scientific advisory board for Codman and receives research support from Pfizer, Elan Corporation, Forest Laboratories, Inc., Medivation, Inc. Janssen, Allon, and the NIH. S. Younkin receives research support from NIH and the Robert and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program. D. Dickson receives research support from the NIH, CurePSP and the State of Florida Department of Elder Affairs Alzheimer Disease Initiative. R. Rademakers receives research support from the NIH, the ALS Association, the ALS Therapy Alliance, CurePSP, and the Consortium for Frontotemporal Degeneration Research. Go to Neurology.org for full disclosures .
PY - 2012/8/14
Y1 - 2012/8/14
UR - http://www.scopus.com/inward/record.url?scp=84866102266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866102266&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318264e3ac
DO - 10.1212/WNL.0b013e318264e3ac
M3 - Comment/debate
C2 - 22855871
AN - SCOPUS:84866102266
VL - 79
SP - 717
EP - 718
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 7
ER -